Recommended for routine testing for lead exposure. For occupational exposure, consider Lead, Industrial Exposure Panel, Adults (0025016).
Quantitative Inductively Coupled Plasma-Mass Spectrometry
New York DOH Approval Status
Royal blue (K2EDTA or Na2EDTA) or tan (K2EDTA).
Transport 7 mL whole blood in the original collection tube (royal blue). (Min: 0.5 mL) OR Transport 3 mL whole blood in the original collection tube (tan). (Min: 0.5 mL)
Room temperature. Also acceptable: Refrigerated.
Serum. Specimens collected in tubes other than Royal Blue (K2EDTA or Na2EDTA) or tan (K2EDTA). Heparinized or clotted specimens. Capillary pediatric EDTA collection tubes, refer to Lead, Blood (Capillary) 0020745.
Trace Elements requisition form may be required (ARUP form #32990).
Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable
Less than or equal to 4.9 µg/dL
Elevated results may be due to skin or collection-related contamination, including the use of a noncertified lead-free tube. If contamination concerns exist due to elevated levels of blood lead, confirmation with a second specimen collected in a certified lead-free tube is recommended.
Information sources for reference intervals and interpretive comments include the "CDC Response to the 2012 Advisory Committee on Childhood Lead Poisoning Prevention Report" and the "Recommendations for Medical Management of Adult Lead Exposure, Environmental Health Perspectives, 2007." Thresholds and time intervals for retesting, medical evaluation, and response vary by state and regulatory body. Contact your State Department of Health and/or applicable regulatory agency for specific guidance on medical management recommendations.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
|All ages||5-9.9 µg/dL||Adverse health effects are possible, particularly in children under 6 years of age and pregnant women. Discuss health risks associated with continued lead exposure. For children and women who are or may become pregnant, reduce lead exposure.|
|All ages||10-19.9 µg/dL||Reduced lead exposure and increased biological monitoring are recommended.|
|All ages||20-69.9 µg/dL||Removal from lead exposure and prompt medical evaluation are recommended. Consider chelation therapy when concentrations exceed 50 µg/dL and symptoms of lead toxicity are present.|
|Less than 19 years of age||Greater than 44.9 µg/dL||Critical. Immediate medical evaluation is recommended. Consider chelation therapy when symptoms of lead toxicity are present.|
|Greater than 19 years of age||Greater than 69.9 µg/dL||Critical. Immediate medical evaluation is recommended. Consider chelation therapy when symptoms of lead toxicity are present.|
Laboratory Developed Test (LDT)
|Component Test Code*||Component Chart Name||LOINC|
|0020098||Lead, Blood (Venous)||77307-7|
- Lead (Adult)
- Pb, Blood
- Pb, Whole Blood
- Venous blood level